Research progress in influence of gender difference on drug therapy of common chronic diseases of the cardiovascular system

doi:10.19803/j.1672-8629.20210413

Abstract

Abstract: Gender-related differences can make a difference to pathogenesis, pharmacokinetics, pharmacodynamics and drug treatment regimens, which is of great significance for prevention and treatment of diseases. Diseases of the circulatory system have become a major health issue that poses a threat to human health in the 21st century. Such databases as CNKI, Wangfang, VIP, PubMed and Web of Science were searched from January 1, 2010 to April 5, 2021. Gender differences in pharmacotherapy of common chronic diseases of the circulatory system (hypertension, chronic cardiac insufficiency, coronary heart disease and atrial fibrillation) were outlined in terms of pathogenesis, pharmacokinetics, pharmacodynamics, efficacy and the incidence of adverse reactions in order to provide reference for individualized medications and promote rational drug use.

Key words: gender difference, diseases of the circulatory system, hypertension, chronic cardiac insufficiency, coronary heart disease, atrial fibrillation, safety

CLC Number:

R994.11

JIANG Ruiqi, MEI Shenghui, ZHAO Zhigang. Research progress in influence of gender difference on drug therapy of common chronic diseases of the cardiovascular system[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1145-1148.

References

[1] ROMANO S, BUCCHERI S, MEHRAN R, et al.Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease[J]. Expert Opin Drug Saf, 2018, 17(10): 1041-1052.
[2] FARKOUH A, RIEDL T, GOTTARDI R, et al.Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature[J]. Adv Ther, 2020, 37(2): 644-655.
[3] WAINER Z, CARCEL C, HICKEY M, et al.Sex and gender in health research: updating policy to reflect evidence[J]. Med J Australia, 2020, 212(2): 57.
[4] HARRISON-WOOLRYCH M.Medicines for women[M]. Springer International Publishing, 2015.
[5] ISLAM MM, IQBAL U, WALTHER BA, et al.Gender-based personalized pharmacotherapy: a systematic review[J]. Arch Gynecol Obstet, 2017, 295(6): 1305-1317.
[6] ROSANO G MC, LEWIS B, AGEWALL S, et al.Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure 1[J]. Eur Heart J, 2015, 36(40): 2677-2680.
[7] WEBER MA, SCHIFFRIN EL, WHITE W B, et al.Clinical practice guidelines for the management of hypertension in the community[J]. The Journal of Clinical Hypertension, 2014, 16(1): 14-26.
[8] ARPON D R, GANDHI M K, MARTIN JH.A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug[J]. Brit J Clin Pharmaco, 2014, 78(2): 274-281.
[9] KALIBALA J, PECHERE-BERTSCHI A, DESMEULES J.Gender differences in crdiovascular pharmacotherapy-the example of hypertension: a mini review[J]. Front Pharmacol, 2020, 11: 564.
[10] SABBATINI AR, KARARIGAS G.Estrogen-related mechanisms in sex differences of hypertension and target organ damage[J]. Biol Sex Differ, 2020, 11(1): 31.
[11] LI L.Analysis of 112 cases of adverse drug reactions induced by antihypertensive drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2012, 9(8): 485-486.
[12] UENO K, SATO H.Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs[J]. Hypertens Res, 2012, 35(3): 245-250.
[13] GUO C, PEI Q I, TAN H, et al.Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients[J].Biomedical Reports, 2015, 3(2): 195-200.
[14] DENTON K M, HILLIARD L M, Tare M.Sex-related differences in hypertension: seek and ye shall find[J]. Hypertension, 2013, 62(4): 674-677.
[15] RYDBERG D M, MEJYR S, LOIKAS D, et al.Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs[J]. Eur J Clin Pharmacol, 2018, 74(9): 1165-1173.
[16] HU S, CHENG J, WEINSTOCK J, et al.A gender-specific association of the polymorphism Ile197Met in the kininogen 1 gene with plasma irbesartan concentrations in Chinese patients with essential hypertension[J].J Hum Hypertens, 2018, 32(11): 781-788.
[17] FAULKNER JL, BELIN DCE.Female Sex, a major risk factor for salt-sensitive hypertension[J]. Curr Hypertens Rep, 2020, 22(12): 99.
[18] ASMAR R, OPARIL S.Comparison of the antihypertensive efficacy of irbesartan//HCTZ and valsartan//HCTZ combination therapy: impact of age and gender[J]. Clin Exp Hypertens, 2010, 32(8): 499-503.
[19] WANG H, CHEN H.Gender difference in the response to valsartan/amlodipine single-pill combination in essential hypertension (China Status II): an observational study[J]. J Renin-Angio-Aldo S, 2016, 17(2): 1878746874.
[20] DEBORDE T, AMAR L, BOBRIE G, et al.Sex differences in antihypertensive treatment in France among 17856 patients in a tertiary hypertension unit[J]. J Hypertens, 2018, 36(4): 939-946.
[21] BENJAMIN EJ, BLAHA MJ, CHIUVE SE, et al.Heart disease and stroke statistics-2017 update: a report from the American Heart Association[J]. Circulation,2017, 135(10): e146-e603.
[22] FRANKENSTEIN L, CLARK AL, RIBEIRO JP.Influence of sex on treatment and outcome in chronic heart failure[J]. Cardiovasc Ther, 2012, 30(3): 182-192.
[23] HAN LL, BAI XJ.Heart failure in women[J]. Chin J Geriatr Heart Brain Vessel Dis(中华老年心脑血管病杂志), 2016, 18(8): 883-886.
[24] KOTECHA D, MANZANO L, KRUM H, et al.Effect of age and sex on efficacy and tolerability of beta blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis[J]. BMJ, 2016, 353: i1855.
[25] NARULA HS, CARLSON HE.Gynaecomastia--pathophysiology, diagnosis and treatment[J]. Nat Rev Endocrinol, 2014, 10(11): 684-698.
[26] WEI Y, OU SP, WU LL, et al.Retrospective analysis of the monitoring results of digoxin blood concentration and its influencing factors[J]. Journal of Modern Medicine & Health(现代医药卫生), 2021, 37(2): 276-278.
[27] MEHTA LS, BECKIE TM, DEVON H A, et al.Acute myocardial infarction in Women[J]. Circulation, 2016, 133(9): 916-947.
[28] FARKOUH A, RIEDL T, GOTTARDI R, et al.Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature[J]. Adv Ther, 2020, 37(2): 644-655.
[29] PLAKOGIANNIS R, ARIF SA.Women versus men: is there equal benefit and safety from statins?[J]. Curr Atheroscler Rep, 2016, 18(2): 6.
[30] Women's Health Group, Chinese society of cardiology.Chinese expert advisory on female antithrombotic therapy[J]. Chinese Journal of Cardiology(中华心血管病杂志), 2020, 48(6): 443-449.
[31] KO D, RAHMAN F, SCHNABEL RB, et al.Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis[J]. Nat Rev Cardiol, 2016, 13(6): 321-332.
[32] KO D, RAHMAN F, MARTINS M AP, et al.Atrial fibrillation in women: treatment[J]. Nat Rev Cardiol, 2017, 14(2): 113-124.
[33] ZELNIKER TA, ARDISSINO M, ANDREOTTI F, et al.Comparison of the efficacy and safety outcomes of edoxaban in 8040 women vrsus 13 065 men with atrial fibrillation in the ENGAGE AF-TIMI 48 trial[J]. Circulation, 2021, 143(7): 673-684.
[34] PALAMANER S S G, MENTIAS A, INAMPUDI C, et al. Sex‐specific associations of oral anticoagulant use and cardiovascular outcomes in patients with atrial fibrillation[J]. J Am Heart Assoc, 2017, 6(8): e006381.
[35] LINDE C, BONGIORNI M G, BIRGERSDOTTER-GREEN U, et al.Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society[J]. Europace, 2018, 20(10): 1565.
[36] ZHONG B, WANG Y, ZHANG G, et al.Environmental iodine content,female sex and age are associated with new-onset amiodarone-induced hypothyroidism: a systematic review and meta-analysis of adverse reactions of amiodarone on the thyroid[J]. Cardiology, 2016, 134(3): 366-371.